Company Odonate, Inc.

ODT

US6760793041

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:44:40 2024-04-25 pm EDT			5-day change	1st Jan Change
18,810 ^USD	+10.00%		+9.22%	+25.40%

2023	North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	DJ
2023	North American Morning Briefing : Stock Futures -2-	DJ

Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Number of employees: 145

Managers	Title	Age	Since
Kevin Tang CEO	Chief Executive Officer	57	12-12-31
Michael Hearne DFI	Director of Finance/CFO	61	14-12-31
Ryan Cole COO	Chief Operating Officer	-	13-12-31
Steven Pfeiffer CTO	Chief Tech/Sci/R&D Officer	48	16-07-31
Christian Gagel AUD	Comptroller/Controller/Auditor	-	20-12-31

Members of the board	Title	Age	Since
Kevin Tang CEO	Chief Executive Officer	57	12-12-31
Craig Johnson BRD	Director/Board Member	62	17-06-30
Aaron Davis BRD	Director/Board Member	45	16-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,925	2,925 ( 100.00 %)	0	100.00 %

Odonate, Inc.

3 East 28th Street 10th floor

10016, New York

+332 206 0935

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ODONATE, INC.	+25.40%	53.42M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals